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Abstract
Introduction: Ischemia-reperfusion injury following cardiopulmonary resuscitation (CPR) is associated with a systemic
inflammatory response, resulting in post-resuscitation disease. In the present study we investigated the response of the
pleiotropic inflammatory cytokine macrophage migration inhibitory factor (MIF) to CPR in patients admitted to the hospital
after out-of-hospital cardiac arrest (OHCA). To describe the magnitude of MIF release, we compared the blood levels from
CPR patients with those obtained in healthy volunteers and with an aged- and gender-matched group of patients
undergoing cardiac surgery with the use of extracorporeal circulation.
Methods: Blood samples of 17 patients with return of spontaneous circulation (ROSC) after OHCA were obtained upon
admission to the intensive care unit, and 6, 12, 24, 72 and 96 h later. Arrest and treatment related data were documented
according to the Utstein style.
Results: In patients after ROSC, MIF levels at admission (475.26157.8 ng/ml) were significantly higher than in healthy
volunteers (12.5616.9 ng/ml, p,0.007) and in patients after cardiac surgery (78.2641.6 ng/ml, p,0.007). Six hours after
admission, MIF levels were decreased by more than 50% (150.56127.2 ng/ml, p,0.007), but were not further reduced in
the subsequent time course and remained significantly higher than the values observed during the ICU stay of cardiac
surgical patients. In this small group of patients, MIF levels could not discriminate between survivors and non-survivors and
were not affected by treatment with mild therapeutic hypothermia.
Conclusion: MIF shows a rapid and pronounced increase following CPR, hence allowing a very early assessment of the
inflammatory response. Further studies are warranted in larger patient groups to determine the prognostic significance of
MIF.
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Introduction
Although the number of patients successfully resuscitated from
cardiac arrest (CA) is increasing, the mortality rate in the post-
resuscitation period is due to the severity of neurological and
myocardial dysfunction still dramatically high [1]. Following
cardiopulmonary resuscitation (CPR), complex changes including
a systemic inflammatory response [2,3], myocardial dysfunction
[4–6], endothelial activation [7], alterations of the coagulation
system [5,8], adrenal insufficiency [9], hyperglycemia [10] and
arterial hypotension [4,11] are frequently observed. Although
some of these features have been described already several decades
ago [12], the importance of the post-cardiac arrest syndrome has
only been recently underscored and highlighted in the latest CPR
guidelines [13]. Interestingly, many of the features, which
characterize the post-cardiac arrest syndrome are also frequently
observed in patients with severe sepsis or septic shock, which has
led to the synonym ‘‘sepsis-like syndrome’’ [14].
Macrophage migration inhibitory factor (MIF) is a pleiotropic
inflammatory cytokine with chemokine-like functions, which is
rapidly released from pre-formed cytoplasmic pools of several cell
types (including monocytes/macrophages, B and T cells, endo-
thelial and epithelial cells and cardiomyocytes), in response to
various noxious stimuli such as infection, inflammation or hypoxia
[15,16]. MIF plays a pivotal role in the control of the acute
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acute and chronic inflammatory conditions, including rheumatoid
arthritis, septic shock, acute respiratory distress syndrome and
atherosclerosis by promoting and amplifying monocyte and
macrophage survival, MAPK signalling and/ or cytokine release
[15,18,20]. In sepsis, inhibition of the MIF pro-inflammatory
activity has previously proven beneficial in numerous animal
models of endotoxemia, and gram-negative and gram-positive
septic shock [21–23]. In addition, recent studies observed a strong
association between poor outcome and high levels of MIF in
patients with severe systemic inflammation, organ failure and/or
acute respiratory distress syndrome [24,25,26].
In an apparent contrast, MIF has been demonstrated to offer
protection from I/R-injury by activating adenosine monophos-
phate-activated protein kinase (AMPK) and inhibiting c-Jun N-
terminal kinase (JNK)-induced apoptosis of cardiomyocytes
[27,28].
Given the central involvement of MIF in immunological
processes linked to I/R-injury, we hypothesized that MIF levels
may exhibit an early increase in patients successfully resuscitated
from OHCA.
We therefore investigated MIF serum levels in patients after out-
of-hospital cardiac arrest (OHCA). To assess the magnitude of
MIF release, we compared MIF serum levels of post cardiac arrest
patients with those obtained in healthy volunteers and with an
aged- and gender-matched group of patients undergoing cardiac
surgery with the use of extracorporeal circulation and cardioplegic
arrest.
Materials and Methods
Patients and study design
After approval of the study by the local institutional review
board committee Aachen, 17 patients with cardiac arrest of non-
traumatic origin and 17 gender- and aged-matched patients
undergoing cardiac surgery with extracorporeal circulation and
cardioplegic arest were consecutively enrolled in this study. The
study was registered at ClinicalTrials.gov (NCT number:
NCT01412619) and the protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1. The included patients after OHCA
represent a random sample of a larger group of patients in which
the influence of MTH on S-100 values after OHCA and predictive
power after OHCA has been recently studied and published [29].
The study complied with the Declaration of Helsinki.
Exclusion criteria were age less than 18 years, severe pre-
existing conditions including sepsis, stroke, previous CPR and
cancer. Cardiac arrest was defined as the absence of respiration,
palpable pulse and responsiveness to stimuli. CPR was performed
in accordance to the European Resuscitation Council’s (ERC)
guidelines 2000, which were gradually replaced during the study
period by the updated guidelines of 2005 [30]. After recovery of
blood pressure and pulse for more than 1 hour after admission to
the hospital, CPR was considered as ‘‘successful’’ and patients
were included in this study.
Treatment of patients
After completion of CPR and admission to the hospital, all
patients were transferred to the intensive care unit (ICU) and
received standardised intensive care treatment including mechan-
ical ventilation, fluid substitution, tight glucose control, sepsis and
vasopressor treatment. Additional interventions (e.g., heart
catheterisation) were carried out if appropriate. The initiation of
mild therapeutic hypothermia (MTH) was left at the discretion of
the attending physicians since not being a standard recommen-
dation in the earlier ERC guidelines. MTH was induced using ice
bags and infusion of cold fluids.
Tracheal extubation was performed when standard extubation
criteria were fulfilled. Patients were discharged from the ICU after
fulfilment of standardized clinical discharge criteria.
Data collection
Baseline characteristics regarding demographic and CPR
related parameters as well as clinical data were collected
immediately after hospital admission in the emergency department
(baseline) and 6, 12, 24, 72 and 120 hours after admission using a
web-based data entry system complying with the Utstein-Style,
initiated by the German Society of Anaesthesia and Intensive Care
Medicine as part of a quality assurance system [31].
A standardized neurological assessment was performed by an
independent physician, using the cerebral performance categories
(CPC) after 14 days. CPC 1 and 2 were considered as favourable
neurological outcome, whereas CPC 3 to 5 labelled adverse
outcome [32].
Table 1. Baseline characteristics for patients after ROSC.
Patients after ROSC
(n=17)
Biometric/Demographic
Data
Age (years) mean 6 SD 70 6 12
median [IQR] 74 [61–79]
Sex, male n (%) 10 (59)
Arrest related data
VF as initial rhythm n (%) 8 (47)
Asystole as initial rhythm n (%) 6 (35)
Cardiac origin n (%) 13 (76)
Call response interval
(mm:ss)
mean 6 SD 03:36 6 01:32
median [IQR] 04:00 [03:00–05:00]
Number of shocks n [IQR] 1 [1–3]
Arrest witnessed n (%) 12 (71)
Location at public place n (%) 5 (29)
Location at home n (%) 11 (65)
Treatment
Early defibrillation n (%) 1 (6)
Bystander CPR n (%) 3 (18)
Mild therapeutic
hypothermia
n (%) 9 (53)
Outcome
Mean survival (days) median [IQR] 81 [52–192]
Survivors n (%) 8 (47)
Good neurological
recovery
n (%) 5 (29)
CPC (n) median [IQR] 5 [2–5]
n=absolute number; (%)=percentage of the whole; IQR=interquartile range;
SD=standard deviation.
VF=ventricular fibrillation; CPR=cardiopulmonary resuscitation; CPC=cerebral
performance categories.
doi:10.1371/journal.pone.0033512.t001
MIF after Resuscitation from Cardiac Arrest
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Serum samples for the determination of C-reactive protein
(CRP), procalcitonin (PCT), tumor necrosis factor alpha (TNF-a)
and interleukin 6 (IL-6) and MIF were taken from the supernatant
of blood collected for routine laboratory analyses at the predefined
time points. The inflammatory cytokines IL-6, TNF-a and the
biomarkers CRP, PCT were quantified using commercially
available automated systems (LIAison, DiaSorin, Dietzenbach,
Germany, and KRYPTOR, Brahms AG, Hennigsdorf, Berlin,
Germany). The serum levels of MIF were determined using an
Table 2. Baseline characteristics for patients after cardiac surgery.
Patients after cardiac surgery
(n=17)
Biometric/Demographic Data
Age (years) mean 6 SD 70 6 11
median [IQR] 74 [61–79]
Sex, male n (%) 10 (59)
Euroscore median [IQR] 5 [2–7]
Type of surgery
Isolated CABG n (%) 6 (35)
Isolated valvular surgery n (%) 3 (18)
Aortic surgery n (%) 1 (6)
Combined procedure n (%) 7 (41)
Duration of surgery (min) median [IQR] 188 [156–254]
Ischemia time (min) mean 6 SD 61.8 6 47.0
median [IQR] 61.0 [41–83]
CPB Time (min) mean 6 SD 108.3 6 71.0
median [IQR] 87 6 [70–125]
n=absolute number; (%)=percentage of the whole; IQR=interquartile range; SD=standard deviation.
CABG=coronary artery bypass graft; CPB=cardiopulmonary bypass.
doi:10.1371/journal.pone.0033512.t002
Figure 1. Comparison of MIF levels in patients after ROSC with those obtained in patients after cardiac surgery. Values are
represented as mean 6SD at predefined timepoints after succesful CPR. MIF levels of healthy volunteers are additionally depicted at the time point
‘‘admission’’. * p,0.007 vs. baseline. 1 p,0.007 vs patients after ROSC. # p,0.007 vs. group of healthy volunteers.
doi:10.1371/journal.pone.0033512.g001
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described [15]. MIF levels of OHCA patients were compared
with MIF values obtained from 30 healthy volunteers [33] and
from 17 patients undergoing elective cardiac surgery at our
hospital. After approval by the institutional review board and
obtainment of written informed consent, the latter were identified
as matched pairs using the variables gender and age. Cardiac
surgery was performed with the use of extracorporeal circulation
and cardioplegic arrest according to our institutional routine as
described previously [34]. Cardiopulmonary bypass (CPB) was
performed in moderate hypothermia (28uC–32uC) on a conven-
tional CPB circuit with cardiac arrest induced by the antegrade
infusion of cold crystalloid cardioplegic solution.
Statistical Analysis
All data were statistically analysed using a commercially
available software package (SPSS 17.0 (SPSS inc., Chicago, IL,
USA). All data are expressed as mean 6 SD.
As primary endpoint, we studied the time course of MIF serum
levels after successful resuscitation.
All data were checked for normal distribution using the
Shapiro-Wilk-test. Differences between groups were compared
using a repeated measurement analysis of variance to take into
account the correlated observations within the groups. As fixed
effects, we included the within-factor time, the grouping factor
pre-study treatment (patients after ROSC vs. patients after cardiac
surgery), and the interaction effect (group * time). The time-course
of the various biomarkers within the OHCA-group was analysed
using one-way-ANOVA. In case of significant results, post-hoc
testing was performed using the Student’s t-test with Bonferroni-
adjustment for multiple measurements. The significance level of
the fixed-effects results was adjusted for multiple hypotheses (i.e.,
for the number of all biomarkers (n=7) tested in the present
investigation and in the study from which the present patients
represent a random sample, see above). Hence, a p,0.007 was
considered to indicate statistical significance.
Results
Patients’ characteristics and cardiac arrest-related data about
treatment and outcome are presented in Table 1.
The characteristics of the matched cardiac surgical patients are
depicted in Table 2. In patients after ROSC, MIF levels at
admission were significantly higher than in healthy volunteers [age
2968 years; male=18 (60%)] and in patients after cardiac surgery
Figure 2. Serum levels of MIF, TNF-a, IL-6 and CRP after
admission to the ICU and 6, 24, 72 and 120 hours later.
*p ,0.007 vs. baseline.
doi:10.1371/journal.pone.0033512.g002
Table 3. Comparison of time course of inflammatory reaction in patients after OHCA and after cardiac surgery as assessed by the
serum levels of procalcitonin (mg/l).
Admission 24 hours 48 hours 72 hours 120 hours
OHCA mean 6
SD
0.21 6 0.35 n=17 7.16 6 11.61 n=13 n.a. 1.89 6 3.18 n=11 0.44 6 0.63 n=7
median
[IQR]
0.08 [0.05 – 0.13] 0.66 [0.19– 3.82] n.a. 0.4 [0.19– 1.2] 0.18 [0.09 – 0.36]
Cardiac
surgery
mean 6
SD
0.58 6 0.74 n=17 4.95 6 13.24 n=17 11.63 6 16.48 n=6 n.a. n.a.
median
[IQR]
0.4 [0.10 – 0.50] 1.30 [0.40– 2.30] 5.45 [1.0 – 10.3] n.a. n.a.
IQR=interquartile range [IQR].
n.a.=not available.
Results of the overall RMANOVA: p=0.71 (group); p=0.02 (time); p=0.59 (interaction).
doi:10.1371/journal.pone.0033512.t003
Figure 3. MIF serum levels in patients who recieved MTH in
comparison with normothermically treated patients. Values are
represented as mean 6SD at predefined timepoints after succesful CPR.
doi:10.1371/journal.pone.0033512.g003
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response-interval and MIF levels upon admission (r=0.652;
p=0.041). Six hours after admission, MIF levels decreased by
more than 50%, but were not further reduced during the following
time course and remained significantly higher than the values
observed during the ICU stay of cardiac surgical patients (Fig. 1).
Of note, MIF levels peaked earlier than those of other
inflammatory cytokines and sepsis markers. In comparison to
CRP, TNF-a and IL-6, MIF showed its highest peak already at
admission and was therefore the first cytokine to peak (Fig. 2). MIF
then showed a second peak 24 h after admission to the hospital,
which was paralleled by an IL-6 peak. In contrast, CRP levels
were constantly increasing after admission. In order to compare
the time course of inflammatory reaction in CPR patients with
that after cardiac surgery, we additionally assessed the postoper-
ative PCT release in the control group consisting of cardiac
surgical patients. In both groups, PCT showed a similar time
course with an increase reaching its maximum at 24–48 hours
after admission to the ICU (Table 3).
The treatment with mild therapeutic hypothermia did not affect
MIF serum levels (Fig. 3). In this small group of patients, MIF
levels were neither able to discriminate between patients with good
and bad neurological outcome nor to distinguish between
survivors and non-survivors (Fig. 4).
Discussion
The results of our study show that patients after OHCA exhibit
a remarkable increase in serum protein levels of the pleiotropic
cytokine MIF, which is positively correlated with the call-response-
interval. MIF levels peak earlier and show a distinct dose/time
response compared to other inflammatory and sepsis markers.
Successful CPR in patients after OHCA regularly elicits an
ischemia/reperfusion-related release of proinflammatory cytokines
and hence provokes a systemic inflammatory response. MIF is
known to be expressed upstream during the inflammatory cascade
[24]. During the pathogenesis of septic diseases, MIF plays a key
role in up-regulating Toll-like receptor-4 (TLR-4), overriding
glucocorticoid activity and stimulating the release of inflammatory
cytokines such as TNF-, IL-1, IL-6 and IL-8 [17,20,24,35–37]. In
fact, we observed MIF to peak in advance of other key
inflammatory cytokines.
MIF is an important mediator of I/R-injury being rapidly
released in response to ischemia. Interestingly, our data indicate
that the magnitude of MIF release is apparently related to the
duration and the extent of ischemia. In our patients having
suffered from total circulatory arrest and hence whole-body
ischemia, MIF levels were correlated with call-response intervals
that can be considered as a surrogate for ischemia time. Moreover,
MIF levels at admission were increased nearly 30-fold in
comparison with healthy volunteers (not having undergone
ischemia), but ‘‘only’’ 9-fold in comparison with gender- and
age-matched patients admitted to the ICU after cardiac surgery
involving cardioplegic arrest and hence (in contrast to the OHCA-
patients suffering from total circulatory arrest) ‘‘only’’ myocardial
ischemia.
Recent evidence indicates that MIF can have both exacerbating
(‘inflammatory’) and protective (‘anti-inflammatory’) effects in
disease [18,15,38], but the mechanisms and details of the
molecular decisions are only partly understood. In the context of
the current study it is noteworthy of mentioning that secreted
myocardial MIF is able to reduce I/R injury by suppressing
apoptotic pathways and by activating the AMPK pathway through
the MIF receptor CD74 [27,28,35].
On the other hand, studies in patients with severe systemic
inflammation, organ failure and/or acute respiratory distress
syndrome observed a strong association between poor outcome
and high levels of MIF, which could be explained by its pro-
inflammatory activity [17,37]. Likewise, studies in patients after
cardiac surgery observed an association between MIF-release and
the occurrence of organ dysfunction during the postoperative
course [25,39]. These at first-sight contradictory observations may
be readily explained by the complexity of the MIF/MIF receptor
system. MIF not only interacts with CD74, but also engages in
high affinity interactions with the chemokine receptors CXCR2
and CXCR4 to drive inflammatory leukocyte recruitment
processes [18,26] and may mediate the inflammatory pathogenesis
of experimental atherosclerosis [26]. Binding of MIF to the
transmembrane protein CD74 induces its phosphorylation and the
recruitment of CD44, that further activates Src family nonreceptor
tyrosine kinases and leads to ERK1/2 phosphorylation [35]. In
addition, MIF has intracellular activities [15] and most recently a
MIF-like homolog, MIF-2 or DDT, has been identified to have
similar but not identical effects in inflammatory disease [40]. In
our limited patient trial circulating MIF levels did not allow to
discriminate between survivors and non-survivors and were not
able to identify patients with good neurological outcome. We
could therefore not confirm that high levels of MIF are closely
linked to the occurrence of adverse events. Likewise, previous
studies also failed to show any differences in the plasma levels of
PCT, IL-6 and CRP in survivors and non-survivors after OHCA
[3].
Interestingly, MTH did not affect MIF plasma levels, while in
previous studies, MTH was associated with a decrease of
inflammatory cytokines [3]. This finding might be attributed to
the fact that the MIF release primarily occurs in direct response to
ischemia and hence prior to the initiation of MTH. In fact, the
largest MIF-peak was observed at admission to the ICU.
We acknowledge that our study is subject to several limitations.
The control-group consisting of healthy volunteers was not age-
matched. However, it is unlikely that the elevation of MIF after
OHCA is merely attributable to an age effect as MIF values after
OHCA were significantly higher than those observed in an age-
matched group after cardiac surgery. Second, the number of
Figure 4. MIF serum levels in survivors and non-survivors.
Values are represented as mean 6SD at predefined timepoints after
succesful CPR.
doi:10.1371/journal.pone.0033512.g004
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statistical power to conclusively elucidate the prognostic signifi-
cance of MIF after OHCA. Our results should therefore be
considered as purely hypothesis-generating. Further studies are
warranted to identify the prognostic role of MIF in a greater
patient population. Our group has recently reported the
prognostic significance of PCT levels in patients suffering from
cardiac arrest [2]. However, MIF determinations in CPR patients
could have a major clinical advantage as MIF peaks in advance to
other inflammatory parameters, and this already at admission to
the hospital. It has to be established whether MIF-determinations
could offer early diagnostic evaluation and stratification of these
patients upon admission to the hospital/intensive care unit. Third,
it would have been very interesting to include a further control
group of patients undergoing cardiovascular surgery with
circulatory arrest and hence transitory whole body ischemia. On
the other hand, validity of this comparison could be questioned
due to the fact that – unlike during cardiac arrest - circulatory
arrest during cardiac surgery is usually performed under the
protection of deep hypothermia.
In conclusion, patients with successful resuscitation after OHCA
show a remarkable increase of MIF serum levels upon admission
to the ICU. MIF is the first cytokine to peak after CPR. Further
studies are warranted to assess the effects on organ dysfunction
and prognostic role of this early MIF peak.
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